Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 5/20 | 0.58 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 11/20 | 0.56 |
| ▸ | NPC1 | O15118 | 10/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4815655 | 1.00 | CRBN (0.58) | CRBNDDB1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL715696 | 0.79 | RAB9A (0.63) | CRBNDDB1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL8526236 | 0.76 | RAB9A (0.73) | RAB9ANPC1SMN1; SMN2POLBCYP1A2 | |
| SCHEMBL30576785 | 0.75 | RAB9A (0.67) | CRBNDDB1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL26606463 | 0.75 | RAB9A (0.67) | CRBNDDB1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6125228 | 0.75 | RAB9A (0.70) | RAB9ANPC1SMN1; SMN2POLBCYP1A2 | |
| SCHEMBL1713549 | 0.74 | RAB9A (0.71) | CRBNRAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL11783793 | 0.74 | RAB9A (0.71) | RAB9ANPC1SMN1; SMN2POLBCYP1A2 | |
| SCHEMBL7217567 | 0.74 | RAB9A (0.71) | RAB9ANPC1SMN1; SMN2POLBCYP1A2 | |
| SCHEMBL23067574 | 0.74 | CRBN (1.00) | CRBNDDB1RAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7402606-B2 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin K inhibitors for the treatment of bone loss | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-22 | — | — | US | claimed |
| US-7288541-B2 | Propylcarbamate derivatives as inhibitors of serine and cysteine proteases | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-30 | — | — | US | claimed |
| US-20050043368-A1 | Propylcarbamate derivatives as inhibitors of serine and cysteine proteases | SMITHKLINE BEECHAM CORPORATION | 2005-02-24 | — | — | US | claimed |
| EP-1494663-A1 | DERIVATIVES OF 1-(OXOAMINOACETYL) PENTYLCARBAMATE AS CATHEPSIN K INHIBITORS FOR THE TREATMENT OF BONE LOSS | SmithKline Beecham Corporation (US) | 2005-01-12 | — | — | EP | claimed |
| WO-2003086385-A1 | DERIVATIVES OF 1-(OXOAMINOACETYL) PENTYLCARBAMATE AS CATHEPSIN K INHIBITORS FOR THE TREATMENT OF BONE LOSS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-23 | — | — | WO | claimed |
| US-7402606-B2 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin K inhibitors for the treatment of bone loss | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-22 | — | — | US | disclosed |
| US-7288541-B2 | Propylcarbamate derivatives as inhibitors of serine and cysteine proteases | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-30 | — | — | US | disclosed |
| US-20050245596-A1 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss | SMITHKLINE BEECHAM CORPORATION | 2005-11-03 | — | — | US | disclosed |
| US-20050043368-A1 | Propylcarbamate derivatives as inhibitors of serine and cysteine proteases | SMITHKLINE BEECHAM CORPORATION | 2005-02-24 | — | — | US | disclosed |
| EP-1494663-A1 | DERIVATIVES OF 1-(OXOAMINOACETYL) PENTYLCARBAMATE AS CATHEPSIN K INHIBITORS FOR THE TREATMENT OF BONE LOSS | SmithKline Beecham Corporation (US) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003086385-A1 | DERIVATIVES OF 1-(OXOAMINOACETYL) PENTYLCARBAMATE AS CATHEPSIN K INHIBITORS FOR THE TREATMENT OF BONE LOSS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043368-A1 | Propylcarbamate derivatives as inhibitors of serine and cysteine proteases | CTSK, CTSB, CTSS | CRBN 1248/4885DDB1 2656/4885RAB9A 3787/4885 |
| US-20050245596-A1 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss | CTSK, CTSB, CTSD | CRBN 4242/4885DDB1 2993/4885RAB9A 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.